Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24802975 | 0.81 | SLC6A4 (0.41) | SLC6A4QDPR | |
| SCHEMBL28905293 | 0.79 | SLC6A4 (0.42) | SLC6A4QDPRKDM4ELMNAPOLB | |
| SCHEMBL31223021 | 0.79 | QDPR (0.44) | SLC6A4QDPR | |
| SCHEMBL16095742 | 0.77 | SLC6A4 (0.52) | SLC6A4QDPRKDM4E | |
| SCHEMBL17897342 | 0.76 | QDPR (0.54) | QDPR | |
| SCHEMBL28664498 | 0.74 | SMN1; SMN2 (0.50) | KDM4ELMNAL3MBTL1 | |
| SCHEMBL18620920 | 0.73 | QDPR (0.47) | QDPR | |
| SCHEMBL22647885 | 0.73 | LIPG (0.53) | POLB | |
| SCHEMBL23850805 | 0.72 | GAA (0.63) | LMNAPOLBL3MBTL1 | |
| SCHEMBL14718661 | 0.72 | SLC6A4 (0.46) | SLC6A4QDPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SLC6A4 4729/4885QDPR 2433/4885KDM4E 1468/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | SLC6A4 4729/4885QDPR 2433/4885KDM4E 1468/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SLC6A4 4729/4885QDPR 2433/4885KDM4E 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.